ランキング価格はじめての方へ
  1. 米国企業
  2. NEUROONE MEDICAL TECHNOLOGIES Corp
  3. Raw

NEUROONE MEDICAL TECHNOLOGIES CorpNMTC

時価総額
$3580.5万
PER
神経疾患向け医療機器開発の新興企業。皮質ストリップ、グリッド、深部電極の薄膜マイクロ電極技術を展開。2024年8月の私募で約265万ドルを調達、同年10月に大手医療機器企業と排他的開発・販売契約を締結。米国中心に展開。
概要財務
サマリーテーブルに戻る
2011年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2019年
9月30日		2020年
9月30日		2021年
9月30日		2022年
9月30日		2023年
9月30日		2024年
9月30日
Net loss-27,604-36,244-62,863-47,775--6,781,161-13,640,160-9,948,168-9,999,613-11,859,491-12,318,110
Amortization and depreciation------47,60980,748118,620199,266246,791
Amortization of deferred issuance costs----------101,329
Stock-based compensation---------11
Fair value change in warrant liability----------327,092
Private placement warrant issuance costs reclassed to financing activities----------127,659
Loss on disposal of fixed assets----------32,143-
Amortization of discounts and premiums on short-term investments--------11,47145,571-
Non-cash lease expense-----------113,534
Accounts receivable-------48,336-15,099-33,237176,636
Inventory-------98,287606,2511908,467
Prepaid expenses-----------47,285
Accounts payable---11,505--66,257-269,601-350,313515,438-247,18966,993
Accrued expenses, deferred revenue, operating lease and other liabilities----------1,225,31316,214
Net cash used in operating activities32,299-----5,395,957-3,425,302-8,602,826-7,519,534-12,886,874-11,011,840
Purchases of short-term investments--------31-
Purchases of property and equipment-----58,352122,42767,079275,226384,117120,197
Net cash (used in) provided by investing activities------123,352-122,427-67,079-3,244,7653-120,197
Proceeds from issuance of common stock in connection with private placement-----5----836,777
Proceeds from issuance of warrants in connection with private placement----------2
Proceeds from issuance of common stock in connection with at-the-market offering program----------5
Issuance costs attributed to common stock and warrants issued in private placement----------1,320
Issuance costs in connection with at-the-market offering program----------236,597
Deferred issuance costs in connection with at-the-market offering program----------20,000
Deferred issuance costs in connection with debt facility----------75,000
Share repurchases for the payment of employee taxes----------81,403
Net cash provided by financing activities46,150----67121277
Net decrease in cash and cash equivalents------431-2,837,836-3,862,451
Unpaid purchases of property and equipment------16,872----
Modification of right-of-use asset and associated lease liability----------199,385
Non-cash warrants issued in connection with debt facility----------53,124
Unpaid issuance costs in connection with private placement----------185,903
Unpaid deferred issuance costs---------4,63195,837